Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Board of Directors of NattoPharma recommends voluntary cash offer by Lesaffre to acquire all shares in NattoPharma

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.Oslo, 15[th] February 2021: Reference is made to the press release dated 2 June 2020 regarding the strategic review of NattoPharma ASA ("NattoPharma" or the "Company") and the engagement of ABG Sundal Collier ASA to investigate various alternatives to maximize shareholder values. Compagnie des Levures Lesaffre (“Lesaffre” or the “Offeror”) and NattoPharma hereby announce that Lesaffre will launch an offer to

DESENIO INTENDS TO CARRY OUT A PRIVATE PLACEMENT AND SUBSEQUENT LISTING OF ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET

NOT FOR PUBLICATION, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, HONG KONG, CANADA, NEW ZEALAND, JAPAN, SWITZERLAND, SOUTH KOREA OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR REQUIRE FURTHER REGISTRATION MEASURES. PLEASE SEE IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Desenio Group AB (publ) (“Desenio” or the “Company”), a fast growing online-based direct-to-consumer (“DTC”) company within the global market for affordable wall art, hereby announces its intention to carry out a

Episealer®: Clinical results with 5-years’ follow-up data to be presented at the 3rd World Arthroplasty Congress

Episurf Medical (Nasdaq: EPIS B) today announces that the scientific report "Clinical results of a patient-specific mini-metal implant for focal cartilage lesions in the knee after 5 years” by Dr. med. Johannes Holz from Orthocentrum, Park-Klinik Manhagen, Hamburg, Germany, has been accepted for presentation at the 3rd World Arthroplasty Congress. The congress is arranged as a digital meeting on April 22-24, 2021. The presentation will be included in the ePosters Knee Session and focuses on clinical results from the use of the Episealer® knee implant.  “This is a great milestone for us

Nitro Games Oyj: Year-end report January – December 2020

Reporting period January – December 2020 · Revenues (Jan-Dec): 1 171,3 KEUR (816,2 KEUR on corresponding period 2019). · EBITDA: -2 326,6 KEUR (-2 658,3 KEUR). · EBIT: -2 783,2 KEUR (-3 284,5 KEUR). · Net profit: -2 810,9 KEUR (-3 293,3 KEUR). · Cash and cash equivalents: 2 981,7 KEUR. October – December 2020 · Revenues (Oct - Dec): 85,8 KEUR (426,6 KEUR). · EBITDA: -877,2 KEUR (-554,6 KEUR). · EBIT: -991,4 KEUR (-711,0 KEUR). · Net profit: -1 004,2 KEUR (-712,0 KEUR). Significant events during October – December 2020 · Nitro Games to develop Nerf

Stora Enso shares converted

STORA ENSO OYJ STOCK EXCHANGE RELEASE 15 February 2021 at 9.00 EET During the 1 January 2021 – 31 January 2021 conversion period there was one conversion and a total of 100 A shares were converted into R shares. The shares were recorded in the Finnish trade register today, 15 February 2021, and trading in the new R shares will start on 16 February 2021.Breakdown of shares after conversion:  A shares 176 254 315R shares 612 365 672Total 788 619 987  Each A share and each ten R shares carry one vote. The total amount of votes after the conversion is at least 237 490

Exercise of employee share options in Atea ASA ("the Company")

Reference is made to the stock announcement dated 10 February 2021.The share capital increase has been registered by the Norwegian Register ofBusiness Enterprises (Foretaksregisteret), and Atea's Articles of association have been revised accordingly. This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Trading Act).   For further information, please contact: Robert Giori, CFO Atea ASA, mobile (+47) 934 09 188Ole Johan Fjellestad, Group Chief Accountant Atea ASA, mobile (+47) 992 74 829

10 guidelines for the promotion of equality in recruitment

Recruitment practices promoting diversity may prove to be a practical solution to the lack of applicants while also reducing unintentional discrimination.Press release by the Finnish Institute of Occupational Health  Discrimination in the recruitment process can be prevented by reforming recruitment practices. Recruitment practices promoting diversity  were published in the Manifold More project of the Finnish Institute of Occupational Health.The practices can increase the diversity sought after by workplaces among

Invent Medic begins market activities in the United States through application for registration of Efemia Bladder Support

Invent Medic announces that the company has submitted an application to FDA for 510(k) market registration of the product Efemia bladder support in the United States. Invent Medic expects to be able to present marketing and sales plans for the product in the United States later in 2021.The overall plan for the company's establishment in the United States is proceeding according to plan. The application for market registration is the beginning of marketing activities in the United States for cooperation on the launch of Efemia bladder support. These establishment plans now also include in

People with and without Alzheimer’s have a different threshold for elective revascularisation, but outcomes are similar

The risk of both mortality and rehospitalisation after an elective revascularisation procedure for coronary artery disease is similar for people with and without Alzheimer’s disease (AD), but people with AD had worse outcomes after an emergency procedure, according to a new study from the University of Eastern Finland. Previous studies have investigated the effectiveness of revascularisation in persons with cognitive disorders, but only in terms of short-term outcomes and in acute care settings, and they also have not accounted for electivity. Similar to previous studies, people with

Invitation to the presentation of Elekta’s third quarter 2020/21

SWEDEN, February 15, 2021 – Elekta (EKTA-B.ST) invites analysts and investors to a presentation of the third quarter 2020/21 at 10:00 a.m. CET on February 25. The interim report for the third quarter will be published at 7:30 a.m. CET on the same day. The company’s development will be presented by Elekta’s President and CEO Gustaf Salford together with acting CFO Johan Adebäck. After the presentation, held in English, a Q&A session will follow. The presentation will be broadcasted live on the web. It will be necessary to join the phone conference if you plan to ask questions. A

Year-end report January–December 2020

JANUARY–DECEMBER 2020 · Income amounted to MSEK 2,035 (1,370), an increase of 46%. · Profit from property management amounted to MSEK 1,334 (1,112), an increase of 20%. · Profit from property management excluding changes in value and tax in joint ventures amounted to MSEK 1,145 (814), an increase of 41%. · Distributable cash flow per share amounted to SEK 6,71 (4.73), an increase of 42%. · Profit after tax amounted to MSEK 2,225 (1,382). · Profit after tax per share amounted to SEK 12.25 (8.24). OCTOBER–DECEMBER 2020 · Income amounted to MSEK 559 (383), an

New knowledge about a cancer pharmaceutical led to the Sjöberg Prize

Benjamin L. Ebert, USA, receives this year’s Sjöberg Prize, worth one million US dollars, for his research into how lenalidomide works as a treatment for blood cancer. His discovery of the mechanism that promotes protein breakdown in cancer cells may be vitally important to the future development of new pharmaceuticals.The story of this pharmaceutical begins with a tragedy as, in the 1950s and 1960s, pregnant women with severe morning sickness were sometimes given thalidomide. This caused a range of birth defects and the medication was removed from the market. Years later, thalidomide

Lower January sales for Clas Ohlson

Sales in January decreased by 9 per cent to 568 MSEK (625). Organic sales decreased by 5 per cent compared to the previous year. Sales in comparable units and local currency decreased by 4 per cent compared to the previous year. Online sales increased by 76 per cent to 70 MSEK (40). Compared to the same month last year the store network was reduced by 2 stores. At the end of the period the total number of stores was 227 (230).Distribution of sales Month Accumulated January Change May - January ChangeMkr

Targovax receives Fast-Track designation for ONCOS-102

· The US FDA grants ONCOS-102 Fast-Track designation for malignant pleural mesothelioma · Fast-Track opens the potential for expedited development and review with the US FDA Oslo, Norway 15 February 2021 – Targovax ASA (OSE: TRVX), a clinical stage immune-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that its lead clinical candidate ONCOS-102 has received Fast-Track designation in malignant pleural mesothelioma from the US FDA.   The US FDA granted Fast-Track designation to ONCOS-102 based on encouraging pre-clinical and

Aker Solutions ASA: Fourth-Quarter Results 2020

February 15, 2021 - Sound orderbook, strong market outlook, growth in energy transition. Aker Solutions and Kvaerner successfully completed the merger in the fourth quarter 2020. Fourth-quarter revenue ended at NOK 6.8 billion and the EBITDA at NOK 121 million, in line with previous communication. Despite the challenging backdrop of the COVID-19 pandemic, the order backlog grew 15 percent compared to in 2019 and ended at NOK 38 billion. The outlook for project sanctioning has improved for 2021 and 2022.4Q 2020 Financial Highlights · Revenues NOK 6.8 billion ex. special items ·

TietoEVRY to divest its Oil & Gas software business

TietoEVRY Corporation            INSIDE INFORMATION           15 February 2021, 8.00 EETTietoEVRY has reached an agreement with Aucerna, a Quorum Software affiliate, to sell its Oil & Gas software business. This divestment is part of the company’s strategy to seek focus and scale. Through this transaction, the Oil & Gas software business will have greater global market reach and growth opportunities. The agreement was reached at an enterprise value of EUR 155 million, implying an EV/Revenue multiple of approximately 3.2.   TietoEVRY’s Oil & Gas software business comprises hydrocarbon

Orkla acquires VitaePro and Oslo Skin Lab

Orkla Health has entered into an agreement to acquire 100% of the shares in NutraQ 2 AS (NutraQ), which is a leading supplier of subscription-based health and beauty products in the Nordic region.NutraQ is behind the two well-known health and beauty concepts VitaePro and Oslo Skin Lab. NutraQ also owns the two Men’s Health brands Maxulin and Provexin, and the Vesterålens Naturprodukter brand that offers omega-3 and various vitamin supplements. “With the acquisition of NutraQ, Orkla is taking a new, important step into a growing health and wellness market. I am impressed by how NutraQ has

Digital Cash enables global interoperability for payment services

Crunchfish is a technical pioneer within digital payment with Digital Cash that settles payments in two steps, first offline and then online. This enables payments that always work and can also be made with preserved integrity. Digital Cash is extremely flexible and complements all types of payment schemes, both on cards and mobiles. Crunchfish now enables internationally interoperable payment services by a global root certificate for Digital Cash. ”With Digital Cash, Crunchfish establishes a new international rail for digital payments that enables different payment services even

MTG confirms that the rights issue is oversubscribed

Not for release, publication or distribution, in whole or in part, directly or indirectly, in or into Australia, Canada, Hong Kong, Japan, New Zealand, South Africa, Singapore, Switzerland, the United States or any other country where such publication, distribution or release would be unlawful or require additional documents to be prepared or registered or require any other actions to be taken, in addition to the requirements under Swedish law. This press release is not a prospectus or an offer for sale of securities. Securities may not be sold in the United States absent registration with

Raute's financial statements, Corporate Governance statement, Non-financial information statement and Remuration report for 2020 published

RAUTE CORPORATION STOCK EXCHANGE RELEASE 12 FEBRUARY 2021 at 10.15 p.m.RAUTE’S FINANCIAL STATEMENTS, CORPORATE GOVERNANCE STATEMENT, NON-FINANCIAL INFORMATION STATEMENT AND REMUNERATION REPORT FOR 2020 PUBLISHEDRaute Corporation’s audited consolidated financial statements for the year 2020 are published on the company’s website. They are available in pdf format at www.raute.com > Investors > Result Center. Printed financial statements can be ordered by email from ir@raute.com.Raute's Corporate Governance Statement, Non-financial Information Statement and Remuneration Report for 2020

Q-Free: Final results of mandatory offer to acquire all shares in Q-Free ASA

(Oslo, 12 February 2021): Reference is made to the mandatory offer (the “Offer”) from Rieber & Søn AS (the “Offeror”) to acquire all shares in Q-Free ASA (“Q-Free” or the “Company”) pursuant to an offer document dated 14 January 2021 (the “Offer Document”). The acceptance period in the Offer expired today, 12 February 2021, at 16:30 (CET). On 12 February 2021, the Offeror received acceptances for 9,531 shares, corresponding to 0.0088% of the share capital and voting rights in the Company. In total, the Offeror had at the time of expiry of the acceptance period in Offer received

Q-Free: Final results of mandatory offer to acquire all shares in Q-Free ASA

(Oslo, 12 February 2021): Reference is made to the mandatory offer (the “Offer”) from Rieber & Søn AS (the “Offeror”) to acquire all shares in Q-Free ASA (“Q-Free” or the “Company”) pursuant to an offer document dated 14 January 2021 (the “Offer Document”). The acceptance period in the Offer expired today, 12 February 2021, at 16:30 (CET). On 12 February 2021, the Offeror received acceptances for 9,531 shares, corresponding to 0.0088% of the share capital and voting rights in the Company. In total, the Offeror had at the time of expiry of the acceptance period in Offer received

Members of Management Team have sold shares held by them in Musti Group plc after the expiration of their lock-up

Musti Group plc                        Press Release           12 February 2021 at 19.40 Members of Management Team have sold shares held by them in Musti Group plc after the expiration of their lock-up In connection with the Initial Public Offering of Musti Group plc, members of the Board of Directors and the Management Team of the company entered into a lock-up agreement according to which they committed, during a period that would end 360 days from the Initial Public Offering, not to dispose of shares in the company held by them. Information on the lock-ups has been presented in

There are no items matching the current filter
There are no more items matching the current filter
Back to top